Celldex Therapeutics (CLDX) Operating Margin (2016 - 2025)
Historic Operating Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 8747.53%.
- Celldex Therapeutics' Operating Margin fell 68933700.0% to 8747.53% in Q2 2025 from the same period last year, while for Sep 2025 it was 9855.38%, marking a year-over-year decrease of 79841100.0%. This contributed to the annual value of 2778.89% for FY2024, which is 5336200.0% down from last year.
- Celldex Therapeutics' Operating Margin amounted to 8747.53% in Q2 2025, which was down 68933700.0% from 9027.19% recorded in Q1 2025.
- Celldex Therapeutics' Operating Margin's 5-year high stood at 386.21% during Q2 2021, with a 5-year trough of 26030.77% in Q1 2024.
- For the 5-year period, Celldex Therapeutics' Operating Margin averaged around 7690.27%, with its median value being 5429.04% (2021).
- Per our database at Business Quant, Celldex Therapeutics' Operating Margin plummeted by -226728600bps in 2024 and then soared by 170035700bps in 2025.
- Quarter analysis of 5 years shows Celldex Therapeutics' Operating Margin stood at 6089.82% in 2021, then skyrocketed by 72bps to 1728.77% in 2022, then soared by 33bps to 1152.92% in 2023, then crashed by -314bps to 4768.26% in 2024, then crashed by -83bps to 8747.53% in 2025.
- Its Operating Margin stands at 8747.53% for Q2 2025, versus 9027.19% for Q1 2025 and 4768.26% for Q4 2024.